Category Archives: Stell Cell Research


1000 Entrepreneurs: Ken Aldrich on 30 Years of Venture Capital and 50 Successful Businesses – GuruFocus.com

Over the last three decades, Ken Aldrich has successfully invested in over 50 businesses and has personally co-founded almost a dozen himself. He considers himself a jack of all trades, having been involved in everything from biomedicine to real estate. Some of his most successful investments include helping start one of the first wind parks in Palm Springs and Green Dot Corp. (NYSE:GDOT), which has become the worlds largest prepaid debit card company. In May, Aldrich published his book, "Dream Toolbox," which aims to guide readers toward establishing an entrepreneurial mind and gaining control over their financial world.

Before the business

Prior to entrenching himself as an entrepreneur, Aldrich started his career as a wage earner practicing law. He spent a great deal of time and effort to earn his law degree and land a spot in a well-established firm. With a clear career path ahead of him, Aldrich got to work earning his keep and establishing his position in the firm. However, one definitive moment stands out as the time when he became dissatisfied with his work.

This moment would revolve around sandwiches of all things. Working alongside one of the senior partners at the firm, Aldrich was helping to create a registration statement for a public company. At the end of the session that fateful day, the underwriters and the people from the company headed out to get dinner:

At the end of the day the company and the firm that was doing the underwriting turned to us, the lawyers, and said Well that was really good. Can we have a new draft of the work in the morning at nine and we will start again? Off they went to have dinner at Chasens and we ordered sandwiches, Aldrich said.

To provide context for those who do not know the Los Angeles restaurant history, Chasens was a well-known restaurant that was often frequented by famous celebrities until its closing in 1995. Based upon the prestige of the restaurant's chili, it is easy to conceive a distaste for sandwiches after a long day at work.

While in his 20s Aldrich did not have an issue eating sandwiches, yet he was thinking toward his future. My partner, that I was working for, was in his 30s or 40s. I do not want to be the guy eating sandwiches in his 30s or 40s, and I do not care how much they pay me for it, Aldrich said. It was in this moment that he decided that he would much prefer to be the guy going out for a nice dinner after work.

With clear motivation, Aldrich set out to find himself a new career path. He landed himself a contractual position at an investment banking firm. This provided him with some needed experience and training, alongside a foot in the door with a name behind him. This new venture would come with an inherent risk, one that Aldrich would feel almost immediately.

Working at the law firm, he had earned himself a paycheck and a solidified position. Upon leaving, that paycheck disappeared. To compound the pressure, Aldrich was working on a contract for the investment banking firm, meaning that if he were to no longer be productive in their eyes, he would be cut from their team. In essence, the already large pay cut he had taken could go away in an instant. He went on to say:

Wide World of Sports had a sports program on Saturday and their opening montage was a skier, it might have been a tobogganer, coming down a ski run and losing control and flying head over heels into a snowbank. The tagline was Wide World of Sports, the thrill of victory and the agony of defeat. I realized that with conventional jobs you are either working for a paycheck or in the case of a lawyer you are measuring your life out in coffee spoons as Eliot once said in a poem. There is never the chance of a real thrill of victory. The expectation is do not screw up and I wanted something more than that.

Finding success

With a drive to succeed and find that thrill of victory, Aldrich set out on his journey to become a successful entrepreneur. By nature of the business, he would find himself in the world of seed stage venture capital, investing and co-founding businesses from the ground up. Through both luck and skill, he was able to grow many of these businesses to success, yet there is seemingly no connection between them. However, Aldrich considers himself a jack of all trades and finds that his curiosity has led him to such diverse portfolio.

While he has found himself invested in many different fields, there is one key factor that ties them all together. If there is technology involved, I want to make sure that if it is successful, often it is not completely developed when we start, but that if it is successful it will make a fundamental change in some business, or industry, or science, Aldrich said. Having this significant change in the way things are done makes either the business or the product stand out in a way that the market cannot deny. For Aldrich, this is key for these types of ventures to be a success.

It is very hard to be successful starting a new business if you are just doing it a little bit better because, you know, everybody is looking for perfect, but perfect is the enemy of the good. If there is an existing process that is serving the market adequately it is usually just a fools errand to try to make something else that is just a little bit better, he continued.

As with many lessons, Aldrich had to learn to make fundamental changes first hand. One of the first businesses he found himself involved in was working to develop a new device for LASIK procedures. This device would allow for the surgeon to be more accurate when applying the procedure. Initially, the company found success in that the device did improve the accuracy of the procedure. However, it was not a big enough difference and nobody cared according to Aldrich.

Going back to the drawing board, the company went about redesigning the product so that it could be an aid to curing amblyopia in children, yet the market there was too small. With the aid of an ocular physician, the company found its true purpose. The new design would allow a surgeon in the process of doing cataract surgery to take an accurate measurement of the eye.

Prior to this new design, the surgeon would attempt to measure the eye through the clouded portion as best as possible before removing the affected area. As the measurement had to be taken through the affected area, it was generally not overly accurate and that is how people ended up with those coke bottle glasses, Aldrich said.

With their newly pioneered technology, the surgeon had a new device that would attach to the microscope that they used during the procedure. This would allow for them to take an accurate measurement of the lens of the eye prior to the surgery. This technology resulted in vision on par with a LASIK procedure as a byproduct of conventional cataract surgery. It was very gratifying for me because I have, over my life, had enough eye problems to realize just how life changing that small procedure can be, Aldrich said. This business would eventually go on to sell for $350 million.

Managing risk

With the prospect of millions, if not billions, on the horizon, there is constant risk involved with starting these businesses. For Aldrich, the key to success comes in managing this risk, although it can never be entirely eliminated. Once he has established that the technology or the business will make a fundamental change in the industry it operates in, he looks toward the people involved. First and foremost, he questions if they have enthusiasm and skin in the game as he calls it. Now that does not necessarily mean that they have written big checks, but they have put some portion of their life on hold to pursue this, he said.

Finding a person who fits these qualities allows for Aldrich to be confident that if things get difficult with the company, nobody is going to give up. In many cases, things do go wrong when starting a business. Very rarely does a business make its way to success without encountering a road bump. At some point everyone has to take some genuine risk. I have never known a startup that did not involve that, Aldrich said.

Over the course of 30 years in business, Aldrich has experienced his fair share of risk and road bumps. One of the most egregious cases that he recalled involved a biotechnology company. The company in question was working to develop new stem cells similar in nature to embryonic stem cells. The winning factor was that the company had found a way to access these cells without needing a fertilized embryo. So we took all, or we thought we took all of them, some people still managed to find objections, but we took basically all the real objections away from those who were concerned, for religious or for other reasons, with whether or not using embryonic stem cells was in effect killing a human being in utero, Aldrich said.

While they had overcome a major roadblock to progress their research, they still had not reached calm seas. The company would go public and found itself in the midst of the economic downturn of 2008. Almost overnight, funding that had been promised had disappeared and the company was left stranded with no backing.

To further compound issues, the CEO of the company died of a heart attack shortly after. Aldrich found himself running the company and as an investor himself. He put forth a check for $500,000, one that would have been very painful to have lost in his own words. In a stroke of luck, he was able to find an investor for the company. However, the man was in Paris, was Russian and spoke no English. Not a man to be stopped, Aldrich flew to Paris, dug up a translator on the eve of a French holiday and made a deal with the new investor.

With the help of this new partner and his own investment, Aldrich would pull the company out of the hole it found itself in. The company would continue to make progress on its stem cell research. Eventually, the majority shareholder of the company would push Aldrich out of a leadership position and he decided it would be best to pull himself out of the company entirely. During his time there, Aldrich would grow the stock from 15 cents per share to over $2 per share.

The biggest perks

While Aldrich has undoubtedly seen rough times working with companies, he has found himself, more often than not, in the position of successfully creating a business. The thrill of just saying, I did that, claimed Aldrich, is one of the best parts of what he does. Continuously, he has had the ability to take the vision that someone brings him and help them turn it into a reality. For him that has been extremely gratifying, yet he has been able to take it one step further.

Many of the companies that he has been involved in have changed people's lives for the better. The first LASIK company aided many people in having better vision, which Aldrich considers life changing. The stem cell company has the potential to change the way stem cells are used, and he believes they ultimately will. Even present day he is working with a company that is working to make chemotherapy drastically more effective to the point that it can cure certain types of cancers.

Without a doubt Aldrich has found the thrill of victory and helped people in the process. Now it is still a whole lot of fun to make money from a deal and see it take off, he said. One of his most ludicrous investments was Green Dot Corp., in which he was an early investor. Since throwing his hat in the ring, the company has not only reached a billion-dollar market cap, it has created an entirely new industry of prepaid debit cards.

Even the wind park in Palm Springs that Aldrich helped start has seen him cashing monthly checks from land rights for the last 20 years. Having both built companies and earned money for decades, it is easy to understand how he has no desire to change anything, yet Aldrich believes that he has no regrets for a different reason.

I think in each case we did the most we could do with what we had available, Aldrich said. In his opinion, there will always be something that could have gone differently or a potential to have found greater success. The reality is I had gone everywhere I could think of and took the option that was available, he continued.

In the end, worrying becomes unproductive. It creates a situation in which you are cautious about your current ventures and begin to question every decision. Aldrich believes this type of fear, the fear of failure, is one that is extremely detrimental to an entrepreneur. Overcoming this fear has been key to his success.

No end in sight

In his most recent ventures, Aldrich has found himself seeking to inspire both youth and entrepreneurs alike. He has spent time working with at-risk teenagers to provide them with financial lessons as well as the skills to develop their dreams into reality. From these lessons, Aldrich developed a podcast series that would eventually become his first book, titled "Dream Toolbox," for anyone frustrated by unfulfilled dreams.

Although Aldrich has had a career outlasting many other entrepreneurs, he does not believe he will ever be able to stop. While he has made a promise to himself to not start any new companies, he will continue to fund and advise them as much as he can:

I can not see stopping because, frankly, it is so darn much fun. I have flunked retirement several times in the sense of really trying to turn it off. What I have discovered is just about the time I am getting all excited to go play a round of golf, or go play tennis or something like that, somebody will call me up with a new idea, or a new concept, and I will cancel the golf or cancel the tennis because nothing is more exciting than dealing with a new idea that has great promise.

Question and answer

GuruFocus: As an entrepreneur, and a serial entrepreneur at that, is there anything in the future coming up or already starting to reach the market that you are really excited about and would love to get your hands on?

Aldrich: My experience has been that the things that are already visible to me, out there in the market, somebody else has already started and is way ahead of me. So what I am looking for are the things that are not yet obvious and those can come in many ways. I recently became an investor in a company. It is not a startup anymore. I invested through some friends, but it is very exciting. They have, I believe, a way to, I will not say cure, but to take any of the existing chemotherapies that are used in cancer and make them way, way more effective, and the reality is, based upon the data we have, in many cases cure cancers that the physicians had given them up as incurable and a death sentence. That is enormously exciting to me and I think that we will see that.

I have also invested, although I am not a principle, in three or four other companies that have varying ways of approaching, particularly cancer, but other disease forms. That to me is an exciting area and I think we are just beginning to scratch the surface of what can be done medically. There are things going on with AI that will affect the medical world. I read in this mornings newspaper about a new AI technique that I think was developed by Google that has greatly improved the accuracy, or looks like it has greatly improved the accuracy of mammograms. That could be life-saving.

GuruFocus: Where do you look for inspiration?

Aldrich: One of the great books and it is overlooked, but I think everybody should read it right after they finish mine, actually before, is "Think and Grow Rich." Which has been around for almost a century, I guess. It is absolutely a brilliant set of ideas and structures for entrepreneurship. There are certainly more modern books. I happen to like Peter Thiels book, which I think he calls "Zero to One." It talks about entrepreneurship and finding a niche that you can fill and expand into making something big. Of course, if you just start looking and get specific, there are tons and tons of books on how to structure a business, how to handle the accounting, finance and so on. Again, I think it starts with changing the belief systems so that you believe you can do it and for that there probably is no better book that I have read than "Think and Grow Rich."

GuruFocus: What are you most grateful for at this point in your life?

Aldrich: Oh wow. I am most grateful that I have had the incredible good fortune to have the love of not one, but two wonderful women in my life. First my wife, who died a few years ago, and second, the woman who is now sharing my life. That has been remarkable. I have also had the good fortune through most of my life of having good health. I have had plenty of health issues that I have had to deal with, but they have all been like the puzzles I talked about. OK, I have a problem. I had a vision problem. I have had other things. How can we solve them? So far, they have all been soluble. I have been very fortunate. As you can see from this ugly photograph on your screen, I am not a young man anymore. I wake up in the morning thinking I am at least 20 or 30 years younger than I am until I look in the mirror. And that is a good thing because age ultimately matters as none of us live forever. In terms of our capacity to do things, it is how we view ourselves, so that is important.

Aldrichs advice for entrepreneurs

Have a vision both personally and in business:

Try to visualize what life would look like if you were to find the success that you have. Once you have this vision, there is something for you to strive for. In Aldrichs opinion, this is one of the most powerful tools an entrepreneur can utilize. Visualize yourself being successful while standing in front of the mirror. It may feel stupid at first, as it did for Aldrich, but you will eventually make that vision a reality by translating it into the present. Use your vision to tell yourself that you are successful now and, before you realize it, you will have reached many of your early milestones.

Put some skin in the game:

It can be simplified to one word: commit. You need to absolutely dedicate yourself to what you are doing if you want to succeed. This will require personal sacrifice. Your life will not continue to exist in the same way that it had previously and you have to be OK with that. Once you have committed your life to achieving your goals and truly put some skin in the game, you will find success. If you do not do this, you are going to give up when things get tough.

Determine if the worst outcome is survivable:

Another of Aldrichs most powerful tools is determining if the worst possible outcome is survivable. Look at the worst thing that could happen in the course of starting this business. Are you looking at bankruptcy? Or could it be something personal that ends life as you know it? Once you have determined what could happen, you need to decide if you have the ability to keep going on after that. If you can survive the worst outcome, than there is nothing that can stop you on your journey. All your problems become puzzles that have a solution. You simply need to find it.

For more information on Ken Aldrich and Dream Toolbox visit:

https://www.dreamtoolbox.com/

If you are an entrepreneur or know one that would be a good fit for our series, please fill out the questionnaire and our editorial team will reach out as soon as possible.

Make sure to check out the podcast.

Watch the video of the entire interview here:

Read more here:

Not a Premium Member of GuruFocus? Sign up for afree 7-day trial here.

More:
1000 Entrepreneurs: Ken Aldrich on 30 Years of Venture Capital and 50 Successful Businesses - GuruFocus.com

Preparing the youth – The News International

Preparing the youth

With the beginning of a new year and a new decade, this is an ideal time to begin thinking about how we as a country our preparing our youth for the future.

As a thought exercise, lets think about the young children aged three and four who will be beginning their early schooling this year. In twenty years, these children will be entering the workforce, which will look very different than it does today.

According to the Future of Jobs Report, it is estimated that 65 percent of children entering primary school today will end up working in jobs that do not currently exist. In light of this uncertainty, an important challenge policymakers must address is to ensure that our education systems and skills development programs reflect the existing and anticipated needs of society and the workforce two decades from now.

To get a sense of how much the world has changed, think of some of the innovations in the past twenty years and how they have impacted society. This includes (but is not limited to) the rapid scale up of internet accessibility, having information at our fingertips with powerful search engines like Google, the introduction of the smart phone, social networking, and the expansion in the applications of artificial intelligence.

We have also witnessed life-changing advancements in medicine such as the sequencing of the human genome, stem cell research, targeted cancer therapies and development of bionic limbs. At the same time, war and conflict, social and environmental movements have also deeply impacted the world in the last two decades. These are exciting times and the rate of advancement isnt linear, its exponential.

As the Future of Jobs reports highlights, the nature of the job market has also been significantly impacted and will continue to be shaped by these developments. And with developments in the applications of artificial intelligence, the loss of jobs due to automation is an increasing concern.

A study by Frey and Osbourne (2013) examined how susceptible jobs are to computerization (or automation) and estimated that 47 percent of total US employment is at risk of being redundant (for the 702 occupations that were studied). What is particularly worrisome is that occupations characterized by low wages and lower education are more susceptible to automation.

It is within this context that we must think about how our education systems and skills programmes are preparing Pakistani youth for the challenges of the future. So what do experts think will be the most in-demand skills for employers in the coming years? According to the Future of Jobs report, the most highly valued skills at the moment as cited by employers are complex problem solving skills and social skills. However, in terms of skills for the future workforce, it is forecasted that the growth in skills demand will be highest for cognitive abilities (that is, creativity, logical reasoning, mathematical reasoning, and cognitive flexibility) and system skills (that is, judgment and decision-making and systems analysis).

The question we must ask ourselves is: what are we doing to equip our youth (and teachers) with these skills? Can we build a digital Pakistan without having a strong foundation in the form of a quality basic education system? This is critical because if we fail to prepare our youth for the future, it is the low skilled, less educated individuals who are the most likely to be left behind.

The writer is an Education Economist, and a Gates-Cambridge scholar.

Read the original here:
Preparing the youth - The News International

Canine Stem Cell Therapy Market Extensive Growth Opportunities to Be Witnessed by 2019-2026 – Fusion Science Academy

Canine Stem Cell Therapy Market (2018) Report Provides an in-depth summary of Canine Stem Cell Therapy Market Status as well as Product Specification, Technology Development, and Key Manufacturers. The Report Gives Detail Analysis on Market concern Like Canine Stem Cell Therapy Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments.

The latest report about the Canine Stem Cell Therapy market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the Canine Stem Cell Therapy market size with regards to the revenue and volume have also been mentioned. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Leading manufacturers of Canine Stem Cell Therapy Market:

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Scope of The Canine Stem Cell Therapy Market Report:

This research report for Canine Stem Cell Therapy Market explores different topics such as product scope, product market by end users or application, product market by region, the market size for the specific product Type, sales and revenue by region forecast the Market size for various segments. The Report provides detailed information regarding the Major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Canine Stem Cell Therapy market. The Canine Stem Cell Therapy Market Report analyzes opportunities in the overall Canine Stem Cell Therapy market for stakeholders by identifying the high-growth segments.

A detailed overview of the geographical and competitive sphere of the Canine Stem Cell Therapy market:

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Table of Content of The Report

Chapter 1- Canine Stem Cell Therapy Industry Overview:

1.1 Definition of Canine Stem Cell Therapy

1.2 Brief Introduction of Major Classifications

1.3 Brief Introduction of Major Applications

1.4 Brief Introduction of Major Regions

Chapter 2- Production Market Analysis:

2.1 Global Production Market Analysis

2.1.1 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

2.1.2 Major Manufacturers Performance and Market Share

2.2 Regional Production Market Analysis

Chapter 3- Sales Market Analysis:

3.1 Global Sales Market Analysis

3.2 Regional Sales Market Analysis

Chapter 4- Consumption Market Analysis:

4.1 Global Consumption Market Analysis

4.2 Regional Consumption Market Analysis

Chapter 5- Production, Sales and Consumption Market Comparison Analysis

Chapter 6- Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7- Major Classification Analysis

Chapter 8- Major Application Analysis

Chapter 9- Industry Chain Analysis:

9.1 Up Stream Industries Analysis

9.2 Manufacturing Analysis

Original post:
Canine Stem Cell Therapy Market Extensive Growth Opportunities to Be Witnessed by 2019-2026 - Fusion Science Academy

Cell Separation Technologies Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 2026 – Dagoretti News

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Cell Separation Technologies Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Cell Separation Technologies market. We have also provided absolute dollar opportunity and other types of market analysis on the global Cell Separation Technologies market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Cell Separation Technologies market. All findings and data on the global Cell Separation Technologies market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Cell Separation Technologies market available in different regions and countries.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2575888&source=atm

The authors of the report have segmented the global Cell Separation Technologies market as per product, application, and region. Segments of the global Cell Separation Technologies market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Cell Separation Technologies market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Cell Separation Technologies Report by Material, Application, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

In this report, the global Cell Separation Technologies market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2023, growing at a CAGR of XX% during the period 2019 to 2023.

The report firstly introduced the Cell Separation Technologies basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:PluriSelect GmbHThermo Fischer ScientificSTEMCELL TechnologiesMitenyi BiotecEMD MilliporeBD Bioscience

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Cell Separation Technologies for each application, including-Oncology ResearchNeuroscience ResearchStem Cell Research

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2575888&source=atm

Cell Separation Technologies Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Cell Separation Technologies Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Cell Separation Technologies Market in South, America region is also expected to grow in near future.

The Cell Separation Technologies Market report highlights is as follows:

This Cell Separation Technologies market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Cell Separation Technologies Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Cell Separation Technologies Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Cell Separation Technologies Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2575888&licType=S&source=atm

Originally posted here:
Cell Separation Technologies Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 2026 - Dagoretti News

Europe’s guardian of stem cells and hopes, real and unrealistic – FRANCE 24

Warsaw (AFP)

Poland has emerged as Europe's leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industry's leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

- Health insurance -

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sister's stem cells into Michal's bloodstream.

It was not quite enough for Michal's needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, "is now flourishing, both intellectually and physically," his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, "each container holds up to 10,000 blood bags... Safe and secure, they wait to be used in the future," its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the "blood will be ready to use without the whole process of looking for a compatible donor and running blood tests," the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns' umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

- Beauty products -

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as "sellers of hope", who "make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons."

He compares them to makers of beauty products who "swear their cream will rejuvenate the client by 20 years."

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

"There is a list of almost 80 diseases for which stem cells could prove beneficial," US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP.

"But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy," he said.

"It's not true, as it's written sometimes, that we can already use them to fight Parkinson's disease or Alzheimer's disease or diabetes."

EuroStemCell also cautions against private blood banks that "advertise services to parents suggesting they should pay to freeze their child's cord blood... in case it's needed later in life."

"Studies show it is highly unlikely that the cord blood will ever be used for their child," the network said.

It also pointed out that there could be a risk of the child's cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries however permit it while imposing strict controls.

- Rapid growth -

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 percent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKM's chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

2020 AFP

See original here:
Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24

Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders – Moneycontrol.com

The Indian Psychiatric Society (IPS) the professional body that represents psychiatrists in India, strongly condemned the use of stem cell therapy in psychiatric disorders, particularly autism, until such a time that research evidence substantiated its effectiveness.

IPS, in its position statement on stem cell therapy on January 17, said that till now, there is no scientifically validated and scrutinized research evidence that proves that stem cells are helpful in any psychiatric disorders including autism.

Autism is a complex neurodevelopmental disorder with no known single cause.

The advisory from the IPS comes at a time when stem cell therapy clinics that claim to have developed stem cell therapies to treat complex psychiatric problems such as autism, cerebral palsy (movement disorder), muscular dystrophy (weakness of muscles), mental retardation, spinal cord injury and brain stroke have mushroomed across the country.

These stem cell therapy centres extract stem cells from the bone marrow of each child and then inject it into the childs spinal canal. The whole procedure takes place under general anaesthesia.

These clinics use aggressive marketing techniques and false claims to lure parents of children who are suffering from disease like autism.

The Indian Council of Medical Research (ICMR) has already published guidelines that cover the various diseases that are applicable for stem cell treatment. No psychiatric disorders, including autism, are listed there under this advisory.

Stem cells are special human cells that have the ability to develop into many different cell types, from muscle cells to brain cells. In some cases, they also have the potential to repair damaged tissues, and provide a cure for various diseases. But the clinical evidence at this point is low.

Psychiatric disorders including autism are combined derangements of both neurodevelopmental and neurodegenerative trajectories of brain and are polygenetic in origin. So they actually are symptomatic manifestations of a variety of different pathogenetic processes about which scientific evidence is as yet inconclusive, IPS said.

The rest is here:
Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com

Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapies – Healio

Helen Tayton-Martin

Astellas Pharma announced a research and commercialization deal with Adaptimmune for the codevelopment of new stem cell-derived allogeneic chimeric antigen receptor and other T-cell therapies for the treatment of cancer.

The two companies have agreed to pursue up to three new research targets and codevelop cell therapy candidates directed toward those targets.

Astellas will use its proprietary Universal Donor Cell and Gene Editing Platform that it acquired with the purchase of Universal Cells.

Adaptimmune had a previous relationship with Universal Cells for the development of gene-edited cells for T-cell therapy. The latest deal broadens that collaboration to include development of gene-edited CARs and T-cell receptors, according to Helen Tayton-Martin, PhD, MBA, chief business officer of Adaptimmune.

Our motivation for making this deal was to accelerate our allogeneic platform, leverage the existing collaboration with Astellas, and to continue our aspiration to broaden out our overall platform from TCRs into CARs, Tayton-Martin told Healio.

Astellas will provide Adaptimmune with an upfront payment of $50 million as part of the deals terms. Additionally, Adaptimmune will receive $7.5 million in research funding each year, and Astellas will finance research of chosen codevelopment targets all the way through to phase 1 proof-of-concept trials. At that point, the companies will have the option to go forward with codevelopment of the candidate treatment, or either company can choose to develop the investigational treatment unilaterally.

There is a lot of flexibility in the deal, but the underlying theme to all of this is that its a co-development and commercialization collaboration, Tayton-Martin said.

The two companies will split the cost of development and commercialization for treatment candidates they decide to codevelop, with the profits to be split equally.

Tayton-Martin did not specify which disease states would be targeted by the research.

Its likely to cover a range of solid tumors, plus some hematological tumors, as well, she said.

The deal, which is effective immediately, could bring in a total of nearly $900 million for Adaptimmune if commercial incentives are achieved. The agreement could total more than a half a billion dollars for Astellas provided it triggers specific commercial incentives. by Drew Amorosi

For more information:

Helen Tayton-Martin, PhD, MBA, can be reached at 60 Jubilee Ave., Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom; e-mail: helen.tayton-martin@adaptimmune.com.

Continue reading here:
Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapies - Healio

Could Scientists ‘Hack’ the Zika Virus to Kill Brain Cancer? – Livescience.com

The mosquito-spread Zika virus known for its links to brain damage in babies born to infected mothers has the potential to target and destroy brain cancer, scientists have found.

New research has revealed that the Zika virus breaks into brain cells by using a special molecular key, and scientists think the virus could be tweaked so that it infects only brain cancer cells, leaving healthy cells unharmed.

The aggressive brain cancer glioblastoma often defies standard cancer treatment because the disease transforms normal brain cells into stem cells. While typical neurons stop dividing after so many replications, stem cells can reproduce indefinitely and grow a whole new tumor from just a handful of cells. Patients typically survive less than 20 months after being diagnosed with glioblastoma; even if the cancer can be forced into remission, the tumors typically regrow and take the life of the patient within 12 months.

But where standard treatments fail, the Zika virus may offer a new strategy to wipe out the deadly disease, according to a pair of studies published Jan. 16 in the journals Cell Reports and Cell Stem Cell.

Related: The 9 Deadliest Viruses on Earth

"While we would likely need to modify the normal Zika virus to make it safer to treat brain tumors, we may also be able to take advantage of the mechanisms the virus uses to destroy cells to improve the way we treat glioblastoma," senior author Dr. Jeremy Rich, director of neuro-oncology and of the Brain Tumor Institute at UC San Diego Health, said in a statement. (Rich and his colleagues authored the Cell Stem Cell paper.)

When the Zika virus infects developing fetuses, the virus stunts brain development by targeting neural stem cells and stunting their proliferation. Rich and his co-authors wondered whether the virus' strategy could be co-opted to shrink brain tumors. In a 2017 study published in The Journal of Experimental Medicine, the team put their theory to the test and found that the Zika virus actually prefers to infect glioblastoma stem cells over normal brain cells at least in petri dishes and mouse models of the disease. The reason behind this preference remained a mystery, until now.

To learn how Zika breaches the membranes of cancer cells, the team scanned the virus' surface for integrins receptors that viruses often use to latch onto their victims' cells and slip inside. Having identified various integrins on the viral surface, the researchers then blocked each with a protein. Then, they unleashed the modified virus into a lab dish holding a mix of normal brain stem cells and cancerous ones. If a particular integrin helped Zika hack into brain cells, blocking the receptor should stop the infectious virus in its tracks.

Through trial-and-error, the team learned that an integrin called v5 serves as the key that lets Zika into brain cells.

"When we blocked other integrins, there was no difference," Rich said. "But with v5, blocking it with an antibody almost completely blocked the ability of the virus to infect brain cancer stem cells and normal brain stem cells."

Related: 5 Facts About Brain Cancer

According to the study, v5 consists of two halves: v and 5. The former half appears in abundance on brain stem cells, which may help to explain how the virus targets both healthy and cancerous brain stem cells. The latter half, however, mostly appears on cancer cells and renders tumors more aggressive, regarding how quickly they can spread.

For this reason, glioblastomas may be more vulnerable to Zika infection than normal brain stem cells. The team confirmed the idea by injecting Zika into human brain organoids tiny models of the human brain grown in a lab dish. In the mini-brains, the virus reliably infected cancer cells more often than healthy cells. But without an intact v5 receptor, the virus could not infect the cells at all.

The second study, published in Cell Reports, also confirmed that v5 grants Zika its cancer-crushing powers.

Using the CRISPR gene-editing technique, the researchers selectively deleted specific genes from glioblastoma stem cells and exposed each mutant tumor to the Zika virus. When they deleted the gene that contained instructions to build v5, Zika could no longer grab hold of the cancer cells. The discovery "made perfect sense" because v5 appears in such large quantities on neural stem cells, the virus' primary target, senior author Tariq Rana, professor and chief of the Division of Genetics in the Department of Pediatrics at UC San Diego School of Medicine and Moores Cancer Center, said in the statement.

Related: 7 Odd Things That Raise Your Risk of Cancer (and 1 That Doesn't)

With the knowledge that v5 may be a soft spot in aggressive glioblastomas, the researchers now aim to genetically modify the Zika virus to target the cancer while sparing healthy cells.

Other deadly viruses could also serve as weapons against brain cancer. In a study published in 2018 in The New England Journal of Medicine, researchers treated glioblastoma patients with a genetically modified poliovirus and found that more than 20% remained alive three years later, as compared with 4 percent of patients who received a standard treatment, Live Science reported at the time. As the field of virotherapy continues to grow, once-deadly diseases may prove to be powerful weapons in the fight against cancer.

Originally published on Live Science.

Here is the original post:
Could Scientists 'Hack' the Zika Virus to Kill Brain Cancer? - Livescience.com

Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti…

In 2019, the market size of Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Therapy .

This report studies the global market size of Stem Cell Therapy , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

This study presents the Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Therapy history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Therapy market, the following companies are covered:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Therapy , with price, sales, revenue and global market share of Stem Cell Therapy in 2017 and 2019.

Chapter 3, the Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

See more here:
Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti...

Stem Cell Cartilage Regeneration Market Report 2019:2026 Industry Growth Forecasts by Manufacturers, Countries, Type and Application Dagoretti News…

The Stem Cell Cartilage Regeneration Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry.

The global Stem Cell Cartilage Regeneration Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Stem Cell Cartilage Regeneration Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Apply Here For Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/2448

Geographical segmentation of Stem Cell Cartilage Regeneration Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Stem Cell Cartilage Regeneration Market: Competitive Landscape

Leading players operating in the global Stem Cell Cartilage Regeneration Market include: Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.

Scope of the Report

The key features of the Stem Cell Cartilage Regeneration Market report 2019-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Stem Cell Cartilage Regeneration Market. The structure of Stem Cell Cartilage Regeneration Market by identifying its various segments and sub-segments to help understanding the report.

Stem Cell Cartilage Regeneration Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Stem Cell Cartilage Regeneration Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Stem Cell Cartilage Regeneration Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2448

Important Stem Cell Cartilage Regeneration Market Data Available In This Report:

Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2448

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

For More Related Reports: http://bit.ly/Rajkumar123

Read the rest here:
Stem Cell Cartilage Regeneration Market Report 2019:2026 Industry Growth Forecasts by Manufacturers, Countries, Type and Application Dagoretti News...